- Efficacy and safety of a novel anti-EGFR ADC MRG003 in recurrent or metastatic squamous cell carcinoma of the head and neck patientsXue, L.; Han, Y.; Zhang, Q.; Li, X.; Fang, M.; Zhong, L.; Wang, S.; Liu, Y.; Zhang, S.; Guo, Y.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
- Phase I study of SHR-A2009, a HER3-targeted ADC, in advanced solid tumorsZhou, Q.; Wu, Y-L.; Li, J.; Liu, A.; Cui, J.; Kuboki, Y.; Yamamoto, N.; Han, S-W.; Lin, G.; Sun, J-M.; Wu, L.; Zhu, Z.; Shuang, J.; Qiu, F.; Shi, W.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
- EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumorsAggarwal, Charu; Azzoli, Christopher G.; Spira, Alexander I.; Solomon, Benjamin J.; Le, Xiuning; Rolfo, Christian; Planchard, David; Felip, Enriqueta; Wu, Yi-Long; Ahn, Myung-Ju; Seiwert, Tanguy Y.; Goto, Koichi; Azaro, Analia; Lissa, Delphine; Hamid, Oday; McGrath, Lara; Maudsley, Rhiannon; Arnaldez, Fernanda I.; Grenga, Italia; Massarelli, ErminiaAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
会议论文
FIH phase I dose escalation and dose expansion study of anti-EGFR ADC MRG003 in patients with advanced solid tumors
7阅读
